EUVIMEDOpdag EUVIMED
FallberichtOpen access · CC BY 4.0

Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience

David C Hutchings iD, Christopher P Denton, Luigi Venetucci, Andrew W Trafford iD

Experimental Physiology · 2025

DOI: 10.1113/ep092932 ↗

At a glance

Fallbericht in Experimental Physiology, 2025. Written by David C Hutchings and 3 co-authors. Institution: Unit of Cardiac Physiology, Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre,…. Major MEDLINE topics: Ventricular Premature Complexes, Phosphodiesterase 5 Inhibitors, Sulfones, Piperazines. Cited 1 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0). Funded by: British Heart Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The phosphodiesterase‐5 inhibitor sildenafil suppresses ventricular arrhythmias in a sheep model of drug‐induced long QT. In that study, ventricular arrhythmias were abolished by reducing premature ventricular complexes (PVCs) and delaying PVC onset, thus preventing ‘R‐on‐T’ ventricular tachycardia. Evidence for effects in humans with arrhythmias is lacking. In this case study, a 50‐year‐old female with a history of PVCs and systemic sclerosis was started on sildenafil for Raynaud's phenomenon in line with current treatment recommendations. During initiation, the patient wore a 7‐day cardiac monitor. Two subtypes of PVCs were observed: one distinct morphology arising 400 ms from the preceding sinus beat (‘late’). Sildenafil abolished late PVCs and substantially reduced the frequency of early PVCs. Of those early PVCs remaining during sildenafil treatment, PVCs arose later in the cardiac cycle, 21 ms further from the preceding T wave apex. During washout, PVCs returned in frequency and timing towards baseline values. We report the first case suggesting an anti‐arrhythmic property of sildenafil in a human.

Subjects

MeSH terms (MEDLINE)

Ventricular Premature ComplexesPhosphodiesterase 5 InhibitorsSulfonesPiperazinesSildenafil CitrateHumansFemaleMiddle AgedPurinesElectrocardiography

Author keywords

arrhythmiaphosphodiesterase‐5sildenafil

Substances

Sildenafil CitratePhosphodiesterase 5 InhibitorsSulfonesPurinesPiperazines

Authors and institutions

  • Unit of Cardiac Physiology, Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, 3.24 Core Technology Facility, University of Manchester, Manchester,…
  • Centre for Rheumatology, Royal Free Campus, NW3 2PS, University College London, London, UK.

ORCID profiles: David C Hutchings, Andrew W Trafford

Funding

  • British Heart Foundation

Cite

APA

Hutchings, D. C., Denton, C. P., Venetucci, L., & Trafford, A. W. (2025). Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience. Experimental Physiology. https://doi.org/10.1113/ep092932

Vancouver

Hutchings DC, Denton CP, Venetucci L, Trafford AW. Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience. Experimental Physiology. 2025. doi:10.1113/ep092932

BibTeX
@article{Hutchings2025,
  author = {Hutchings, David C and Denton, Christopher P and Venetucci, Luigi and Trafford, Andrew W},
  title = {Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience},
  journal = {Experimental Physiology},
  year = {2025},
  doi = {10.1113/ep092932}
}
Start for free →